Latest News and Press Releases

EVOLVE104, a First-in-Class CD2 Costimulatory Trispecific T Cell Engager, is First Molecule from EVOLVE Platform to Enter the Clinic Trial Initiation Marks EvolveImmune’s Transition to Clinical-Stage...

First Program from EVOLVE T-Cell Engager Platform to Advance into Clinical Development Phase 1 Clinical Trial of EVOLVE104 to be Initiated in 2025 BRANFORD, Conn., Aug. 14, 2025 (GLOBE NEWSWIRE)...

BRANFORD, Conn. and NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing next-generation T cell engager biotherapeutics to overcome cancer...

Poster Presentations Spotlight Differentiated Therapeutic Profile and Precision Therapeutic Strategy for Lead Development Candidate EVOLVE104 as Program Advances Toward Clinic for Solid Tumors EVOLVE...

NORTH CHICAGO, Ill. and BRANFORD, Conn., Oct. 31, 2024 (GLOBE NEWSWIRE) -- AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics to...

Multiple Presentations on Lead Development Candidate EVOLVE104 to Showcase Preclinical Safety and Efficacy Profile and Precision Therapeutic Strategy as Company Advances Program Toward Clinic for...

Fundraising Includes Strategic Investment by Bristol Myers Squibb Coupled with Support from Existing Investors EvolveImmune Initiates Chemistry, Manufacturing, and Control (CMC) Activities for Lead...

BRANFORD, Conn., Nov. 06, 2023 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome the therapeutic...

EvolveImmune to Highlight New Data on Precision Medicine Potential of Evolve Platform and Lead Development Programs in Presentations at SITC 2023

BRANFORD, Conn., June 14, 2023 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome cancer-driven...